Do analysts recommend IRD or AADI?

Opus Genetics currently has a consensus price target of $12.29, suggesting a potential upside of 199.65%. Given Opus Genetics' stronger consensus rating and higher probable upside, research analysts plainly believe Opus Genetics is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Opus Genetics 1 Sell rating(s) 1 Hold rating(s) 16 Buy rating(s) 1 Strong Buy rating(s) 2.89 Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer AADI or OCGN?

Ocugen has a consensus price target of $9.50, indicating a potential upside of 1,029.34%. Given Ocugen's stronger consensus rating and higher possible upside, analysts plainly believe Ocugen is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Ocugen 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60

Is AADI or OCGN more profitable?

Ocugen has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Aadi Bioscience -246.06% -71.87% -57.28% Ocugen N/A -127,987.80% -115.95%

Do analysts prefer CABA or AADI?

Cabaletta Bio currently has a consensus price target of $15.60, indicating a potential upside of 862.96%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Cabaletta Bio is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cabaletta Bio 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.89 Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer ARTV or AADI?

Artiva Biotherapeutics currently has a consensus target price of $39.00, indicating a potential upside of 559.90%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Artiva Biotherapeutics is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artiva Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate AADI or CYPH?

Cypherpunk Technologies has a consensus target price of $4.90, suggesting a potential upside of 87.02%. Given Cypherpunk Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Cypherpunk Technologies is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cypherpunk Technologies 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Aadi Bioscience (AADI) Competitors

$2.97 -0.05 (-1.66%)

As of 10/14/2026

Compare

AADI vs. IRD, OCGN, CABA, ARTV, and CYPH

Should you buy Aadi Bioscience stock or one of its competitors? Aadi Bioscience's main competitors and comparable companies include Opus Genetics (IRD), Ocugen (OCGN), Cabaletta Bio (CABA), Artiva Biotherapeutics (ARTV), and Cypherpunk Technologies (CYPH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aadi Bioscience compare to Opus Genetics?

Opus Genetics (NASDAQ:IRD) and Aadi Bioscience (NASDAQ:AADI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

Opus Genetics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

Opus Genetics currently has a consensus price target of $12.29, suggesting a potential upside of 199.65%. Given Opus Genetics' stronger consensus rating and higher probable upside, research analysts plainly believe Opus Genetics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.89
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Opus Genetics had 5 more articles in the media than Aadi Bioscience. MarketBeat recorded 5 mentions for Opus Genetics and 0 mentions for Aadi Bioscience. Opus Genetics' average media sentiment score of 0.73 beat Aadi Bioscience's score of 0.00 indicating that Opus Genetics is being referred to more favorably in the media.

Company	Overall Sentiment
Opus Genetics	Positive
Aadi Bioscience	Neutral

Opus Genetics has higher earnings, but lower revenue than Aadi Bioscience. Opus Genetics is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$9.86M	34.38	-$49.59M	-$1.35	N/A
Aadi Bioscience	$25.07M	2.98	-$65.76M	-$2.35	N/A

15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by insiders. Comparatively, 37.3% of Aadi Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Aadi Bioscience has a net margin of -246.06% compared to Opus Genetics' net margin of -1,091.82%. Opus Genetics' return on equity of 0.00% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-1,091.82%	N/A	-150.13%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Summary

Opus Genetics beats Aadi Bioscience on 10 of the 17 factors compared between the two stocks.

How does Aadi Bioscience compare to Ocugen?

Aadi Bioscience (NASDAQ:AADI) and Ocugen (NASDAQ:OCGN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by company insiders. Comparatively, 4.0% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Ocugen had 11 more articles in the media than Aadi Bioscience. MarketBeat recorded 11 mentions for Ocugen and 0 mentions for Aadi Bioscience. Ocugen's average media sentiment score of 0.27 beat Aadi Bioscience's score of 0.00 indicating that Ocugen is being referred to more favorably in the news media.

Company	Overall Sentiment
Aadi Bioscience	Neutral
Ocugen	Neutral

Ocugen has a consensus price target of $9.50, indicating a potential upside of 1,029.34%. Given Ocugen's stronger consensus rating and higher possible upside, analysts plainly believe Ocugen is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Aadi Bioscience has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, Ocugen has a beta of 2.27, meaning that its share price is 127% more volatile than the broader market.

Aadi Bioscience has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	2.98	-$65.76M	-$2.35	N/A
Ocugen	$4.41M	64.68	-$67.85M	-$0.26	N/A

Ocugen has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Ocugen	N/A	-127,987.80%	-115.95%

Summary

Ocugen beats Aadi Bioscience on 9 of the 15 factors compared between the two stocks.

How does Aadi Bioscience compare to Cabaletta Bio?

Cabaletta Bio (NASDAQ:CABA) and Aadi Bioscience (NASDAQ:AADI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Cabaletta Bio currently has a consensus price target of $15.60, indicating a potential upside of 862.96%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Cabaletta Bio is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Cabaletta Bio has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-128.27%	-95.47%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Cabaletta Bio has a beta of 3.48, suggesting that its share price is 248% more volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

In the previous week, Cabaletta Bio had 2 more articles in the media than Aadi Bioscience. MarketBeat recorded 2 mentions for Cabaletta Bio and 0 mentions for Aadi Bioscience. Cabaletta Bio's average media sentiment score of 1.01 beat Aadi Bioscience's score of 0.00 indicating that Cabaletta Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Cabaletta Bio	Positive
Aadi Bioscience	Neutral

52.1% of Aadi Bioscience shares are owned by institutional investors. 6.4% of Cabaletta Bio shares are owned by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Aadi Bioscience has higher revenue and earnings than Cabaletta Bio. Aadi Bioscience is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A
Aadi Bioscience	$25.07M	2.98	-$65.76M	-$2.35	N/A

Summary

Cabaletta Bio beats Aadi Bioscience on 9 of the 15 factors compared between the two stocks.

How does Aadi Bioscience compare to Artiva Biotherapeutics?

Artiva Biotherapeutics (NASDAQ:ARTV) and Aadi Bioscience (NASDAQ:AADI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

In the previous week, Artiva Biotherapeutics had 7 more articles in the media than Aadi Bioscience. MarketBeat recorded 7 mentions for Artiva Biotherapeutics and 0 mentions for Aadi Bioscience. Artiva Biotherapeutics' average media sentiment score of 0.63 beat Aadi Bioscience's score of 0.00 indicating that Artiva Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Artiva Biotherapeutics	Positive
Aadi Bioscience	Neutral

Aadi Bioscience has higher revenue and earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	1,155.76	-$83.86M	-$3.30	N/A
Aadi Bioscience	$25.07M	2.98	-$65.76M	-$2.35	N/A

Artiva Biotherapeutics has a beta of 2.4, meaning that its stock price is 140% more volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

52.1% of Aadi Bioscience shares are held by institutional investors. 1.8% of Artiva Biotherapeutics shares are held by insiders. Comparatively, 37.3% of Aadi Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Artiva Biotherapeutics has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Artiva Biotherapeutics' return on equity of -53.86% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-53.86%	-48.16%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Artiva Biotherapeutics currently has a consensus target price of $39.00, indicating a potential upside of 559.90%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Artiva Biotherapeutics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Artiva Biotherapeutics beats Aadi Bioscience on 11 of the 16 factors compared between the two stocks.

How does Aadi Bioscience compare to Cypherpunk Technologies?

Aadi Bioscience (NASDAQ:AADI) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

Cypherpunk Technologies has lower revenue, but higher earnings than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	2.98	-$65.76M	-$2.35	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	$0.56	4.68

Cypherpunk Technologies has a consensus target price of $4.90, suggesting a potential upside of 87.02%. Given Cypherpunk Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Cypherpunk Technologies is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aadi Bioscience has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by company insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Cypherpunk Technologies has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Cypherpunk Technologies' return on equity of -20.76% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Cypherpunk Technologies	N/A	-20.76%	-19.48%

In the previous week, Cypherpunk Technologies had 1 more articles in the media than Aadi Bioscience. MarketBeat recorded 1 mentions for Cypherpunk Technologies and 0 mentions for Aadi Bioscience. Cypherpunk Technologies' average media sentiment score of 1.74 beat Aadi Bioscience's score of 0.00 indicating that Cypherpunk Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Aadi Bioscience	Neutral
Cypherpunk Technologies	Very Positive

Summary

Cypherpunk Technologies beats Aadi Bioscience on 12 of the 15 factors compared between the two stocks.

Get Aadi Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AADI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AADI vs. The Competition

Export

Metric	Aadi Bioscience	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$73.35M	$3.97B	$7.44B	$12.94B
Dividend Yield	N/A	3.65%	2.52%	19.59%
P/E Ratio	-1.30	12.70	275.00	25.39
Price / Sales	2.93	1,140.14	569.10	75.48
Price / Cash	N/A	119.79	76.68	52.75
Price / Book	0.69	15.79	10.32	6.02
Net Income	-$65.76M	-$22.69M	$3.49B	$380.68M
7 Day Performance	-12.90%	-4.35%	-2.50%	-3.01%
1 Month Performance	-27.03%	-11.51%	-6.83%	-5.61%
1 Year Performance	50.76%	4.60%	1.85%	-5.24%

Aadi Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AADI Aadi Bioscience	N/A	$2.97 -1.7%	N/A	+49.5%	$73.35M	$25.07M	N/A	40
IRD Opus Genetics	2.6457 of 5 stars	$4.38 flat	$12.29 +180.5%	+105.0%	$362M	$14.20M	N/A	28
OCGN Ocugen	1.881 of 5 stars	$1.04 flat	$9.50 +813.5%	-48.4%	$352.67M	$4.41M	N/A	116	News Coverage Insider Trade
CABA Cabaletta Bio	2.7516 of 5 stars	$2.02 -2.9%	$15.33 +659.1%	-43.9%	$352.65M	N/A	N/A	158	Positive News
ARTV Artiva Biotherapeutics	3.1776 of 5 stars	$7.27 +2.0%	$39.00 +436.5%	+105.9%	$348.59M	$250K	N/A	115

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AADI) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aadi Bioscience (AADI) Competitors

AADI vs. IRD, OCGN, CABA, ARTV, and CYPH

How does Aadi Bioscience compare to Opus Genetics?

Summary

How does Aadi Bioscience compare to Ocugen?

Summary

How does Aadi Bioscience compare to Cabaletta Bio?

Summary

How does Aadi Bioscience compare to Artiva Biotherapeutics?

Summary

How does Aadi Bioscience compare to Cypherpunk Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AADI vs. The Competition

Aadi Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aadi Bioscience (AADI) Competitors

AADI vs. IRD, OCGN, CABA, ARTV, and CYPH

How does Aadi Bioscience compare to Opus Genetics?

Which has more risk and volatility, IRD or AADI?

Do analysts recommend IRD or AADI?

Does the media favor IRD or AADI?

Which has preferable valuation & earnings, IRD or AADI?

Do institutionals & insiders have more ownership in IRD or AADI?

Is IRD or AADI more profitable?

Summary

How does Aadi Bioscience compare to Ocugen?

Do insiders & institutionals believe in AADI or OCGN?

Does the media refer more to AADI or OCGN?

Do analysts prefer AADI or OCGN?

Which has more risk and volatility, AADI or OCGN?

Which has better valuation & earnings, AADI or OCGN?

Is AADI or OCGN more profitable?

Summary

How does Aadi Bioscience compare to Cabaletta Bio?

Do analysts prefer CABA or AADI?

Is CABA or AADI more profitable?

Which has more risk and volatility, CABA or AADI?

Does the media favor CABA or AADI?

Do insiders & institutionals have more ownership in CABA or AADI?

Which has higher valuation & earnings, CABA or AADI?

Summary

How does Aadi Bioscience compare to Artiva Biotherapeutics?

Does the media favor ARTV or AADI?

Which has higher earnings & valuation, ARTV or AADI?

Which has more volatility & risk, ARTV or AADI?

Do institutionals & insiders believe in ARTV or AADI?

Is ARTV or AADI more profitable?

Do analysts prefer ARTV or AADI?

Summary

How does Aadi Bioscience compare to Cypherpunk Technologies?

Which has better earnings and valuation, AADI or CYPH?

Do analysts rate AADI or CYPH?

Which has more volatility & risk, AADI or CYPH?

Do insiders & institutionals have more ownership in AADI or CYPH?

Is AADI or CYPH more profitable?

Does the media prefer AADI or CYPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AADI vs. The Competition

Aadi Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools